COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

PRevention Of BLeeding in hEmatological Malignancies With Antifibrinolytic (Epsilon Aminocaproic Acid) (PROBLEMA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02074436
Recruitment Status : Recruiting
First Posted : February 28, 2014
Last Update Posted : May 10, 2019
Information provided by (Responsible Party):
Ana G. Antun, MD, Emory University

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : May 2021
Estimated Study Completion Date : May 2021
2. Gernsheimer, TB Platelet transfusion in the 21st century, ISBT 2011;6: 245-248
3. Paolo Rebulla, M.D., Guido Finazzi, M.D., Francesca Marangoni, M.D., Giuseppe Avvisati, M.D., Luigi Gugliotta, M.D., Gianni Tognoni, M.D., Tiziano Barbui, M.D., Franco Mandelli, M.D., and Girolamo Sirchia, M.D. for the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto N Engl J Med 1997; 337:1870-187